Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective

For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $90.

Source link

Related posts

Does elevated RVEDP cause dyspnea ?


Sitting Time, Physical Activity, and Risk of Mortality in Adults


From Intervention to Prevention: Dr. Pierre P. Leimgruber to Join the Heart Attack & Stroke Prevention Center in April


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy